A phase III study assessing CYTO-203 for multiple sclerosis
Latest Information Update: 18 Feb 2021
At a glance
- Drugs STAT 203 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Statera BioPharma
Most Recent Events
- 18 Feb 2021 New trial record